A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.

ABSTRACT:

Objective

To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52-week, open-label extension (OLE) study.

Background

Rimegepant is an oral small molecule calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine and the preventive treatment of episodic migraine in adults. The efficacy and safety of rimegepant for preventive treatment of migraine was demonstrated in a 12-week, phase 2/3, randomized, double-blind (DB), placebo-controlled trial in which rimegepant treatment produced significant improvement in the number of monthly migraine days (MMDs) with a safety profile similar to placebo.

Methods

In the DB trial period, an initi

SUBMITTER: Kudrow D 

PROVIDER: S-EPMC12916460 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature